[ALC] Alcon: Q3 2026 earnings test for IOL growth and margins

Alcon, the largest company by sales in both global eye surgery and vision care, is scheduled to report Alcon Q3 2026 earnings on 2026-11-11, covering the third quarter 2026, the three months ended September 30, 2026, according to its earnings calendar[1]. In the latest disclosed quarter, the second quarter of 2026, net sales were $2.782 billion, up 8% reported and 7% at constant currency; core operating margin was 20.6% versus 19.1% a year earlier, and core diluted EPS was $0.84 versus $0.76. The termination of the PowerVision programs, however, produced a $402 million pre-tax non-cash net charge that cut the IFRS operating margin to 0.4% and diluted EPS to $0.00[2][3]. Alcon gives only full-year guidance, not quarterly guidance; in August it maintained 2026 constant-currency net sales growth of 5% to 7%, raised the core operating margin improvement to 90 to 190 basis points and raised core diluted EPS growth to 12% to 15%[4]. The consensus compiled by the Drillr earnings calendar for the third quarter is $2.684 billion of net sales and EPS of $0.89[1], while the average EPS forecast of 9 analysts is $0.859[5]. Neither EPS figure states whether it is on a core basis, and $2.684 billion is about 3.7% above Alcon's third-quarter 2025 net sales of $2.589 billion on a reported basis.

Three things matter most in this report. The first is whether Implantables, the segment line that holds intraocular lenses, can hold constant-currency growth of at least 2%: it grew only 1% in the second quarter, with IOLs up 2% and surgical glaucoma a drag, while U.S. cataract volumes were flat and several competitors launched new lenses[6][7]. That line decides whether Surgical revenue can support the middle of the full-year guidance range. The second is whether the equipment replacement cycle can continue against a harder comparison: Equipment/other grew 24% at constant currency in the first half, but the third quarter of 2025 already carried 13% growth, and management flagged tougher equipment comparisons in the second half[8]. Equipment growth and the Surgical segment contribution margin together will show whether replacements are expanding the installed base or diluting profit. The third is whether core operating margin can exceed the first-half level of 20.9%: Alcon has said it anticipates a higher margin in the second half than in the first, but the second quarter included $15 million of one-time licensing revenue, and roughly two-thirds of the approximately $60 million third-quarter tariff refund is slated for reinvestment[9][10]. Net of those items, the balance between TRYPTYR launch spending and efficiency savings is what determines whether the full-year margin guidance holds.

Company Background and Business Structure

Alcon is an independent eye care company that began as a pharmacy and went through a Novartis acquisition and spin-off. Its predecessor was a pharmacy founded in Fort Worth, Texas, in 1945; Novartis acquired it fully in 2011, and after the 2019 spin-off from Novartis it listed on the SIX Swiss Exchange and the New York Stock Exchange, with headquarters in Geneva, Switzerland[11]. The company has more than 25,000 employees, operates in more than 140 countries and territories, invested $990 million in research and development in 2025, and is led by CEO David J. Endicott[11][12].

Revenue is split into two reporting segments, and the surgical segment relies on its installed equipment base to drive recurring use of consumables and lenses. The Surgical segment generated $5.751 billion in 2025, selling a full range of products for cataract, vitreoretinal, refractive and glaucoma surgery directly to hospitals and ambulatory surgical centers[13][14]: Implantables (intraocular lenses and glaucoma stents) at $1.782 billion, Consumables (the instruments, fluids and cassettes used in each procedure) at $3.028 billion, and Equipment/other (surgical consoles, microscopes, diagnostic equipment and service) at $941 million[13]. The installed equipment base drives continued use of consumables and lenses[15], and advanced-technology IOLs (AT-IOLs) are patient-paid and carry higher gross margins[16]. The Vision Care segment generated $4.568 billion, including $2.770 billion of contact lenses and $1.798 billion of Ocular health; the latter includes over-the-counter products such as Systane artificial tears, sold through pharmacies and retailers, as well as prescription drugs such as TRYPTYR and glaucoma medicines[13][14].

Alcon's manufacturing is largely in-house and concentrated outside the United States, even though the U.S. is its largest single market. About 90% of products are made in its own 16 plants, 9 for Surgical and 7 for Vision Care, most of them outside the U.S.[17]; the U.S. accounted for 45% of 2025 net sales, and no single customer exceeded 10% of sales[18][14]. Costs consist mainly of manufacturing, selling expenses behind new launches, and research and development at about 9% of sales; in 2025 the IFRS gross margin was 55.7%, the core gross margin was 62.7%, and operating cash flow was $2.271 billion[19][20][21].

Financial History and Current Position

For full-year 2025, Alcon's revenue grew steadily, but its core margin slipped slightly from the prior year. Net sales were $10.319 billion, up 5% from $9.836 billion in 2024, with Surgical at $5.751 billion (+4%) and Vision Care at $4.568 billion (+6%)[13][22]. IFRS operating income was $1.360 billion, a 13.2% margin versus 14.4% a year earlier; core operating income was $2.039 billion, a 19.8% core margin versus 20.6%; IFRS net income was $980 million and core net income was $1.521 billion[23][19].

Cash flow was steadier than margins, and free cash flow rose again in 2025. Operating cash flow was $2.271 billion, capital expenditure was $543 million and free cash flow was $1.733 billion, up from $1.604 billion; research and development spending was $990 million, up from $876 million in 2024[20][12]. At the end of 2025, the average maturity of financial debt was 8.8 years and 97% of it carried fixed rates[24].

In the first half of 2026, the core margin recovered while IFRS profit was pulled down by a one-time impairment, so the two measures need to be read separately. Second-quarter net sales were $2.782 billion (+8%, +7% at constant currency), core operating income was $574 million with a 20.6% margin versus 19.1%, and core EPS was $0.84 versus $0.76; the $402 million pre-tax non-cash net charge for ending PowerVision lowered the IFRS operating margin to 0.4% and diluted EPS to $0.00[2][25][3]. First-half net sales were $5.467 billion (+7% at constant currency), the core operating margin was 20.9%, operating cash flow was $928 million and free cash flow was $693 million versus $681 million a year earlier[2][26]. Net debt was $3.248 billion at the end of June, up from $3.125 billion at the start of the year; in the second quarter Alcon returned $469 million to shareholders, including $174 million of dividends and $295 million of buybacks, and about $1.2 billion remained of the $1.5 billion repurchase authorization approved in May 2026[27][26][28].

Operating Model

Alcon's net sales are the sum of five product lines, and procedure volumes, share, AT-IOL mix and equipment placements jointly set Surgical revenue. Net sales combine Surgical's Implantables, Consumables and Equipment/other with Vision Care's Contact lenses and Ocular health; equipment revenue is recognized once at delivery, while consumables and lenses generate recurring revenue with procedure volumes after installation, so changes in equipment sales reach consumables and lenses only after a lag of several quarters[15]. Vision Care revenue depends on the number of contact lens wearers, share, premiums on new platforms and price increases, plus over-the-counter eye drop sales and the ramp of prescription drugs. In the second quarter of 2026, the five lines were Implantables at $466 million, Consumables at $825 million, Equipment/other at $279 million, Contact lenses at $726 million and Ocular health at $486 million[6][29].

Core operating income depends on the gap between core gross profit and launch and R&D spending, and a rising equipment mix lowers gross margin. Core operating income equals core gross profit minus selling, general, administrative and R&D expenses, plus or minus other income and expense, excluding amortization of intangibles, impairments, restructuring and acquisition-related items; the core gross margin is shaped by pricing, manufacturing efficiency, tariffs and equipment mix, while spending is driven mainly by new launches and R&D at about 9% of sales[19][21]. Segment contribution excludes corporate costs and amortization and runs at about 25% of sales for Surgical and about 22% to 23% for Vision Care[30]. In the second quarter of 2026, the core gross margin was 64.7%, up 250 basis points, and the core operating margin was 20.6%; the IFRS operating margin was 0.4% in the same quarter, with the gap coming mainly from the $402 million PowerVision charge and $128 million of amortization[9][25].

Cash flow starts from core net income plus depreciation and amortization, and it funds capital expenditure, dividends, buybacks and small acquisitions. Operating cash flow adds depreciation and amortization back to core net income and subtracts working capital, with receivables rising alongside equipment and consumables sales and inventory rising with launch stocking[20]. Capital expenditure runs at a mid-single-digit percentage of sales, dividends equal about 10% of the prior year's core net income, the $1.5 billion buyback authorized in May 2026 is set to run over three years, and remaining cash goes to single-product tuck-in acquisitions[28][26]. About 55% of sales come from outside the U.S., so reported figures move with currencies, which is why Alcon guides on constant-currency growth[18][4].

Industry and Competitive Position

Alcon is the largest company in both of its markets, but competition concentrates on its two most profitable areas, premium lenses and contact lenses. By 2025 sales, Alcon ranks first in both global surgical eye care and vision care[11]. Its main surgical competitors are Carl Zeiss Meditec, Bausch + Lomb, Hoya, Glaukos and Johnson & Johnson, with competition focused on premium lenses and surgical equipment and several competitors newly entering the AT-IOL market[31][32]; Alcon's advantage is an installed base that covers the full surgical workflow and drives use of consumables and lenses[15].

Competition in vision care is more fragmented, and China's volume-based procurement puts price pressure on intraocular lenses. Alcon's main vision care competitors are Johnson & Johnson, Bausch + Lomb and CooperVision, and its ocular health products also compete with AbbVie's Allergan[33]; about two-thirds of contact lens wearers use reusable lenses, a segment Alcon targets with PRECISION7 and TOTAL30[34][35]. About 6% of sales come from China, where intraocular lenses face volume-based procurement price cuts and a preference for local suppliers[36][37]. The available material offers only a list of competitors and Alcon's own share statements, without comparable revenue or share figures for rivals, so Alcon's lead over each competitor cannot be quantified.

Core Debates

Can PanOptix Pro and Alcon's new lenses restore implantable growth while competitors launch new IOLs and U.S. cataract volumes stay flat?

Intraocular lenses are the weakest part of Alcon's surgical business, and their growth decides whether revenue lands in the middle of full-year guidance. Implantables and Consumables together generated $4.810 billion in 2025, close to half of revenue, and they are Alcon's highest-margin businesses; Implantables were essentially flat in 2025 and grew only 1% at constant currency in both the first and second quarters of 2026[13][38][6]. Within Alcon's 5% to 7% revenue guidance, this is the slowest-growing line[4].

Current evidence shows premium upgrades lifting IOLs, while competition and glaucoma reimbursement offset them. About 90% of legacy PanOptix accounts in the U.S. have converted to PanOptix Pro, U.S. AT-IOL penetration rose 180 basis points for a second consecutive quarter (110 basis points globally), and IOLs grew 2% at constant currency in the second quarter[39][7]. Demand for the Hydrus surgical glaucoma stent fell sharply after reimbursement cuts, international competitive pressure persists, U.S. cataract volumes were flat and global volumes grew only low single digits[32][7]. According to Alcon's third-quarter 2025 figures released in November 2025, Implantables were $432 million a year ago with 2% constant-currency growth, and Consumables were $745 million with 5% growth; in the second quarter of 2026, Consumables were $825 million, up 5% at constant currency[6]. An alternative reading is that IOL growth comes mainly from higher prices as customers upgrade to premium lenses while monofocal share keeps slipping, so growth would fade once the upgrade cycle is complete, and with Vivity Pro and TruPlus not launching until late 2026 to 2027, the third quarter has no new driver[39][40].

The financial transmission runs from flat U.S. procedure volumes and competing premium lens launches to Alcon's lens share and premium mix, then to Implantables and Consumables revenue, and finally to Surgical revenue and core gross profit. In the third quarter, watch whether Implantables grow at least 2% at constant currency, whether Alcon discloses IOL growth separately from the surgical glaucoma drag, and the direction of U.S. cataract volumes and AT-IOL penetration. If Implantables growth falls below 0% at constant currency, competitive erosion is outweighing the upgrade cycle; if U.S. volumes turn negative and consumables growth falls below 3%, the problem has spread from share to procedure demand itself.

Can the UNITY replacement cycle keep equipment growing against a tougher comparison without diluting Surgical profitability?

Equipment is a small share of revenue but was the main source of first-half growth, and it is also what weighs on the surgical segment's margin. Equipment/other is about 9% of sales, grew 24% at constant currency in the first half of 2026 as the fastest-growing line, and contributed about $111 million, or roughly 45%, of the $244 million first-half increase in Surgical revenue[6][38]. Equipment carries lower gross margins than lenses and consumables, and the second-quarter Surgical segment contribution margin was 25.0%, 1 percentage point below 26.0% a year earlier[30]; yet a larger installed base makes later use of consumables and lenses more durable[15].

Management describes the replacement pace positively, but part of the first-half surge reflects an easy comparison. Second-quarter Equipment/other revenue was $279 million, up 25% at constant currency; management said UNITY VCS pricing was better than anticipated and second-half placement visibility was clear, described replacement across about 30,000 eligible installed units over a roughly 10-year cycle, and reported the first sale of the UNITY M microscope[6][39][7]. Alcon has not disclosed unit placements[41]. According to Alcon's third-quarter 2025 figures released in November 2025, Equipment/other was $243 million a year ago with 13% constant-currency growth, and the Surgical segment contribution margin was about 25.1% ($357 million on $1.420 billion of sales), while fourth-quarter 2025 equipment growth was 18%[42]. An alternative reading is that the 2025 first-half equipment decline created an easy base, so growth naturally slows as comparisons stiffen in the second half, and slower growth would not necessarily mean slower replacements[8].

The transmission has two paths: UNITY VCS/CS replacing Constellation/Centurion sets placements and pricing, which set Equipment/other revenue; a higher equipment mix lowers the core gross margin and the Surgical segment contribution margin, while the larger installed base lifts consumable and lens use over later quarters. In the third quarter, watch whether Equipment/other keeps growing above 10% at constant currency, whether the Surgical segment contribution margin stays at or above 25.1%, and how management describes the UNITY CS placement pace. If equipment growth falls below 10%, the replacement cycle is slowing; if the segment contribution margin falls below 24.1%, equipment is diluting profit.

Can Alcon's new contact lens platforms and price increases keep offsetting legacy declines and slower international pricing?

Contact lenses are Alcon's largest single product line, and their growth decides whether Vision Care can keep pace with Surgical. Contact lens revenue was $2.770 billion in 2025, or 26.8% of total sales[13]; the line grew 9% in 2024, slowed to 6% in 2025 and grew only 4% at constant currency in the first half of 2026[13][29].

New platforms and price increases support current growth, but slower international pricing and legacy losses push the other way. Second-quarter contact lens revenue was $726 million, up 5% on both reported and constant-currency bases, driven by new products and price increases and partly offset by legacy declines[29]. Management cited a record global share, PRECISION7 sales more than doubling year over year, continued daily-disposable share gains for TOTAL1 and PRECISION1, and a wider addressable group for TOTAL30 for astigmatism and presbyopia, and said it has scaled back promotion of legacy products[43][7][42]. The global contact lens market grew mid-single digits in the second quarter, with the U.S. strong and international markets slower and price-driven[7]. According to Alcon's third-quarter 2025 figures released in November 2025, contact lenses were $707 million a year ago, up 5% at constant currency. An alternative reading is that growth rests mainly on price, that it will slow as international pricing room narrows, that share gains are concentrated in reusable lenses, and that older DAILIES daily lenses are still losing ground; management, for its part, pointed to an easier contact lens comparison in the fourth quarter[8].

The transmission runs from share and astigmatism and presbyopia mix on new platforms such as PRECISION1/7, TOTAL30 and TOTAL1, plus price increases, minus legacy declines and slower international pricing, to Contact lenses revenue and then Vision Care revenue. In the third quarter, watch whether contact lenses grow at least 4% at constant currency, whether management still reports share gains, and whether international price growth keeps slowing. If growth falls below 3%, share or pricing is weakening; if the international pricing slowdown spreads to the U.S., the price support is fading.

Can TRYPTYR keep ramping and help Alcon deliver its 90-190 basis-point core margin expansion in the second half?

Ocular health is one of the fastest-growing lines, and the raised full-year margin guidance depends on second-half delivery. Ocular health grew 11% at constant currency in the first half of 2026; in August Alcon raised its full-year core operating margin improvement to 90 to 190 basis points and core EPS growth to 12% to 15%, and said it anticipates a higher second-half margin than in the first half[29][4][8]. On quarterly sales of about $2.7 billion, each 1 percentage point of core margin corresponds to roughly $27 million of core operating income.

There is evidence of both a prescription ramp and margin improvement, but the second-quarter margin included one-time items. Less than a year after launch, TRYPTYR holds about 5% prescription share and has access covering about two-thirds of commercial lives and 20% of Medicare lives, while Systane posted double-digit growth in the second quarter[43]; second-quarter Ocular health revenue was $486 million, up 12% at constant currency[29]. The second-quarter core gross margin was 64.7% (+250 basis points), including $15 million of one-time licensing revenue, against a prior-year quarter with elevated inventory-related costs[9][25]; the first-half core operating margin was 20.9%[2]. According to Alcon's third-quarter 2025 figures released in November 2025, Ocular health was $462 million a year ago, up 7%, the core operating margin was 20.2%, and the Vision Care segment contribution margin was about 22.0% ($257 million on $1.169 billion); in the second quarter of 2026, the Vision Care contribution margin was 23.3%, against 18.5% a year earlier that included product discontinuation charges[30]. An alternative reading is that part of the second-quarter margin gain came from one-time revenue and an easy base, that most of the roughly $60 million third-quarter tariff refund will be reinvested, and that, net of these items, TRYPTYR launch spending could leave the underlying margin gain smaller than the headline figure[8][10].

There are two transmission paths: wider TRYPTYR coverage and Systane share drive Ocular health revenue and Vision Care segment contribution; the tariff refund (about $60 million, roughly two-thirds reinvested) and efficiency savings, minus launch spending, set the core operating margin and then core EPS. The efficiency program announced in February targets about $100 million of annualized savings, about $50 million of it in 2026, at a cost of about $150 million[21]. In the third quarter, watch whether Ocular health grows at least 10% at constant currency, whether the core operating margin exceeds the first-half 20.9%, and whether TRYPTYR's Medicare coverage widens. A core margin below 20.9% would mean the second-half margin improvement has not arrived; Ocular health growth below 8% would mean the TRYPTYR ramp is slowing.

Risks and Falsifiers

Tariffs and currencies are the most direct external drivers of gross margin. Alcon makes most of its products in Switzerland, Belgium, Ireland, Germany, Singapore, Malaysia and Indonesia and imports them into the U.S., which provides 45% of sales[17][18]; its 2026 net tariff impact of $40 million to $90 million already includes the roughly $60 million third-quarter refund and assumes U.S. import tariff rates of 10% to 12.5% stay unchanged[10]. The exposure is cost of sales and core gross margin, and changes in tariff rates or the refund would directly affect full-year core operating margin guidance; the current understanding holds if the third-quarter report confirms the refund was received and the full-year net tariff impact stays within $40 million to $90 million.

Impairment risk from R&D and acquisitions hits IFRS profit and shapes how capital is split between buybacks and deals. In the second quarter of 2026 Alcon ended the PowerVision accommodating lens programs and recorded a $402 million pre-tax non-cash net charge[3]; in January 2026 it terminated its agreement to acquire STAAR for about $1.8 billion[44], and it continues to favor single-product tuck-ins of $50 million to $500 million while facing procurement price cuts in China[40][36]. The exposure is IFRS operating income and EPS, with a second-quarter IFRS operating margin of 0.4% and diluted EPS of $0.00, and the pace at which the roughly $1.2 billion left on the $1.5 billion buyback authorization is used[2][26]; the current understanding holds if the third quarter brings no new major impairment and the gap between IFRS and core operating income returns to a normal level dominated by amortization.

Premium lens competition and surgical glaucoma reimbursement are the direct pressures on Implantables. Several competitors have entered the AT-IOL market, Hydrus demand has fallen sharply after reimbursement cuts, and management sees the reimbursement situation staying unchanged in the near term[32][31]. The exposure is Implantables revenue of $1.782 billion in 2025 and the high-margin mix, and with flat U.S. procedure volumes any share loss shows up directly as lower revenue[13][6]; the current understanding holds if Implantables grow at least 2% at constant currency in the third and fourth quarters and management continues to describe U.S. share as stabilizing.

The equipment purchasing cycle makes equipment revenue volatile and dilutes margins as its share of the mix rises. Hospital and surgery center capital budgets set the pace of placements, and quarterly equipment revenue swings widely[18][21]; the exposure is Equipment/other revenue of $941 million and Surgical segment contribution of $1.460 billion in 2025[13][22][30]. The current understanding holds if third-quarter equipment growth is at least 10% at constant currency and the Surgical segment contribution margin stays at or above 25.1%.

Contact lens competition and channel shifts could erode pricing power. Johnson & Johnson, Bausch + Lomb and CooperVision are the main rivals, Asian manufacturers are entering, online channels amplify price comparison, and international price growth has already slowed[33][14][32]. The exposure is contact lens revenue of $2.770 billion in 2025 and Vision Care segment contribution; the current understanding holds if constant-currency growth is at least 4% in the third and fourth quarters and management continues to report share gains.

The prescription drug ramp depends on insurance coverage, and launch spending comes before revenue. TRYPTYR's Medicare Part D coverage is only about 20%, and U.S. drug pricing policy, including Medicare price reform, could lower net prices[43][37]. The exposure is Ocular health revenue of $1.798 billion in 2025, Vision Care segment contribution and the group core operating margin[30]; the current understanding holds if third-quarter Ocular health growth is at least 10% at constant currency and the Vision Care segment contribution margin is at least 22.0%.

What to Watch Next

The indicators below map each core debate to what the third-quarter report can confirm or contradict.

• IOL growth: Implantables grew 2% at constant currency in the third quarter of 2025 ($432 million) and 1% in the second quarter of 2026 ($466 million). Watch for at least 2% growth and separate disclosure of IOLs and surgical glaucoma; a drop below 0% would mean competition is outweighing the upgrade cycle.
• IOL growth: U.S. cataract volumes were flat, U.S. AT-IOL penetration rose 180 basis points and Consumables grew 5%. Watch the direction of volumes and penetration; declining U.S. volumes with consumables growth below 3% would contradict the current view.
• UNITY and margins: Equipment/other grew 13% in the third quarter of 2025 ($243 million) and 25% in the second quarter of 2026. Watch for growth above 10% and management commentary on UNITY CS placements; growth below 10% would signal a slower replacement cycle.
• UNITY and margins: the Surgical segment contribution margin was about 25.1% in the third quarter of 2025 and 25.0% in the second quarter of 2026. Watch for a level of at least 25.1%; a figure below 24.1% would show equipment diluting profit.
• Contact lens pricing and mix: contact lenses grew 5% in the third quarter of 2025 ($707 million) and 5% in the second quarter of 2026. Watch for at least 4% growth plus share and international pricing commentary; growth below 3%, or the international slowdown spreading to the U.S., would contradict the current view.
• TRYPTYR and margin guidance: Ocular health grew 7% in the third quarter of 2025 ($462 million) and 12% in the second quarter of 2026. Watch for at least 10% growth and wider Medicare coverage; growth below 8% would signal a slower ramp.
• TRYPTYR and margin guidance: the core operating margin was 20.2% in the third quarter of 2025 and 20.9% in the first half of 2026. Watch for a margin above 20.9% and receipt of the tariff refund; a margin below 20.9% would mean the second-half improvement has not arrived.

Conclusion

Alcon's business is driven by procedure volumes, premium lens mix, equipment placements and contact lens share and pricing, and its finances are sound, though its growth now leans on equipment and a new drug. In 2025 Alcon generated $10.319 billion of revenue and $1.733 billion of free cash flow, and in the second quarter of 2026 revenue grew 8% while the core operating margin returned to 20.6%[13][20][2]; at the same time, the highest-margin Implantables line grew only 1%, and fast-growing equipment is lowering the Surgical segment contribution margin[6][30]. The central open question is whether growth from equipment replacement and the TRYPTYR ramp can turn into the 90 to 190 basis points of core margin improvement Alcon has guided, amid lens competition and flat procedure volumes[4].

Between the second-quarter release on August 10, 2026 and now, no signed, independently argued outside assessment of Alcon has surfaced; public coverage consisted mainly of restated results and secondhand reports of Pershing Square's new second-quarter stake, neither of which amounts to independent analysis, so there are no outside views to compare for agreement or conflict. Readers can judge these debates only from the company's own disclosures and the third-quarter revenue and EPS figures compiled by the earnings calendar[1].

The current understanding would strengthen materially if third-quarter Implantables growth returns to 2% or more at constant currency, equipment growth stays above 10% while the Surgical segment contribution margin holds at or above 25.1%, the core operating margin exceeds the first-half 20.9%, and the tariff refund arrives as planned. It would weaken if Implantables slip below zero growth, equipment growth falls below 10% or the segment contribution margin drops below 24.1%, the core operating margin comes in below 20.9%, or contact lens growth falls below 3%, since any of these would show that lens competition, the replacement cycle or launch spending is undermining the basis for this year's margin improvement.

Sources

[1] ALC earnings calendar updated 2026-11-09 · 2026-11-09 · Drillr earnings calendar

[2] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · Q2 2026 key figures · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[3] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · PowerVision discontinuation charge · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[4] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · 2026 outlook as of August · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[5] Drillr analyst estimates ALC Q3 2026 retrieved 2026-11-09 · 2026-11-09 · Drillr 分析师预测汇总 · https://gateway.drillr.ai/mcp/private

[6] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · Q2 2026 Surgical net sales drivers · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[7] ALC Q2 2026 earnings call 2026-08-11 · market growth, cataract volumes and AT-IOL penetration · 2026-08-11 · earnings-call · https://gateway.drillr.ai/mcp/private

[8] ALC Q2 2026 earnings call 2026-08-11 · guidance update and second-half phasing · 2026-08-11 · earnings-call · https://gateway.drillr.ai/mcp/private

[9] ALC Q2 2026 earnings call 2026-08-11 · Q2 core gross margin drivers · 2026-08-11 · earnings-call · https://gateway.drillr.ai/mcp/private

[10] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · 2026 outlook assumptions and Q3 tariff refund · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[11] ALC 20-F filed 2026-02-24 · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[12] ALC 20-F filed 2026-02-24 · R&D investment · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[13] ALC 20-F filed 2026-02-24 · FY2025 net sales by product · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[14] ALC 20-F filed 2026-02-24 · sales channels and customers · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[15] ALC 20-F filed 2026-02-24 · installed base drives IOL and consumables · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[16] ALC 20-F filed 2026-02-24 · surgical market drivers and AT-IOL penetration · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[17] ALC 20-F filed 2026-02-24 · manufacturing footprint · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[18] ALC 20-F filed 2026-02-24 · US share of net sales and seasonality · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[19] ALC 20-F filed 2026-02-24 · FY2025 IFRS to core reconciliation · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[20] ALC 20-F filed 2026-02-24 · FY2025 free cash flow · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[21] ALC Q4 2025 earnings call 2026-02-25 · 2026 guidance, efficiency program and gross margin · 2026-02-25 · earnings-call · https://gateway.drillr.ai/mcp/private

[22] ALC 20-F filed 2026-02-24 · FY2025 segment contribution · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[23] ALC 20-F filed 2026-02-24 · FY2025 operating income and margin · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[24] ALC 20-F filed 2026-02-24 · debt maturity and liquidity · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[25] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · Q2 2026 core operating income · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[26] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · H1 2026 cash flow and capital returns · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[27] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · net debt at June 30 2026 · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[28] ALC 6-K filed 2026-05-05 (Q1 2026 earnings release) · USD 1.5 billion share repurchase authorization · 2026-05-05 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000022/q12026pressrelease.htm

[29] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · Q2 2026 Vision Care net sales drivers · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[30] ALC 6-K filed 2026-08-10 (Q2 2026 earnings release) · Q2 2026 segment contribution · 2026-08-10 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000030/q22026pressrelease.htm

[31] ALC 20-F filed 2026-02-24 · surgical competitors · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[32] ALC Q2 2026 earnings call 2026-08-11 · risks: IOL competition, glaucoma reimbursement and surgeon capacity · 2026-08-11 · earnings-call · https://gateway.drillr.ai/mcp/private

[33] ALC 20-F filed 2026-02-24 · vision care competitors · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[34] ALC 20-F filed 2026-02-24 · vision care market size and drivers · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[35] ALC 20-F filed 2026-02-24 · near-term portfolio strategy · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[36] ALC 20-F filed 2026-02-24 · China share and VBP · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[37] ALC 20-F filed 2026-02-24 · pricing, reimbursement and VBP risk · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[38] ALC 6-K filed 2026-05-05 (Q1 2026 earnings release) · Q1 2026 net sales by product · 2026-05-05 · 6-K · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000022/q12026pressrelease.htm

[39] ALC Q2 2026 earnings call 2026-08-11 · Q&A on Unity installed base and IOL share · 2026-08-11 · earnings-call · https://gateway.drillr.ai/mcp/private

[40] ALC Q1 2026 earnings call 2026-05-06 · Q&A on China IOL, glaucoma and Q2 SG&A phasing · 2026-05-06 · earnings-call · https://gateway.drillr.ai/mcp/private

[41] ALC 20-F filed 2026-02-24 · Unity CS introduction · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm

[42] ALC Q4 2025 earnings call 2026-02-25 · Tryptyr launch and contact lens promotion · 2026-02-25 · earnings-call · https://gateway.drillr.ai/mcp/private

[43] ALC Q2 2026 earnings call 2026-08-11 · Unity, PanOptix Pro, TRYPTYR and contact lens launches · 2026-08-11 · earnings-call · https://gateway.drillr.ai/mcp/private

[44] ALC 20-F filed 2026-02-24 · terminated STAAR acquisition · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/1167379/000116737926000014/alc-20251231.htm